
GlaxoSmithKline and rival AstraZeneca have both received positive updates from the US Food and Drug Administration for two drugs.
(Picture: PA)GlaxoSmithKline and AstraZeneca have secured victories with the US regulator in relation to treatments that could become blockbuster drugs for the firms.
Glaxo’s Daprodustat, which is used for the treatment of anaemia in chronic kidney disease patient, has had its application for approval accepted by the Food and Drug Administration (FDA) in the US after its successful phase III clinical trial.